Business Wire

SPINE-INNOVATIONS

28.3.2022 13:24:13 CEST | Business Wire | Press release

Share
Spine Innovations Marks Milestone — Over 20,000 ESP Spinal Discs Implanted — as Global Demand Grows

Since its formation as a wholly independent company in late 2020, Spine Innovations has continued to expand sales of its ESP spinal disc replacements, with more than 20,000 prostheses successfully implanted in patients around the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220328005394/en/

At the same time, Spine Innovations continues to expand its market reach. The company is now active in 17 countries, including new markets within Europe that opened in 2021. It will expand into Central and South America, including Mexico and Brazil, as well as additional European countries, including Norway and the Netherlands. In 2022, Spine Innovations is also working toward FDA approval to enter the US market.

Spine Innovations’ growth has been energized by operating like a startup and hyper-specializing in total spinal disc replacement and the preservation of natural motion. The company’s Cervical Prosthesis (CP-ESP®) and Lumbar Prosthesis (LP-ESP®) utilize a viscoelastic design — recognized as the latest generation of disc replacement — to mimic the function and range of movements of a natural disc and allow the spine to behave naturally.

Increasing, widespread interest in ESP disc replacements, and their swift acceptance by orthopedic surgeons, neurosurgeons, and patients, highlight the strong desire for products that can restore health and quality of life.

ESP discs combine two titanium end plates with an elastomeric cushion made of polycarbonate urethane. This structure imitates the natural disc, in which bony segments are connected by a spongy disc that provides flexibility while withstanding the pressures of compression and torsion. Specific features of the end plates — short spikes, a rough outer surface, and a coating of hydroxyapatite (HA), which is proven to enhance bone ingrowth — help to ensure stability and bony fixation of the implant over time.

“With the ESP, the patients gain a counter force which is similar to what the natural disc provides and reduces risks of facet pain.” Dr. Svante Berg from Stockholm, Sweden, says Remobilization of the disc space with too much mobility can lead to such side effect.

Pr. Jean Yves Lazennec of Pitie-Salpetriere Hospital in Paris says, “The ESP discs reproduce the natural center of rotation and adapt when the patient is aging.”

The entire team of Spine Innovations is focused on satisfying growing market demand. Sandrine Carle President, says “More and more surgeons are choosing to replace degenerative discs with prostheses that can maintain spinal motion instead of fusing the segment. ESP disc replacements provide that solution by replicating natural disc motion and enabling the entire spine to behave as normally as possible.”

---------------------------------------------

Based in Heimsbrunn (France), Spine Innovations continues to increase market penetration and aims to become a leading actor in the total disc replacement worldwide market with its patented viscoelastic technology used in the ESP discs. To learn more, please visit www.spine-innovations.com and www.esp-disc.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye